SCHEMBL5008971

SCHEMBL5008971

O=C(O)c1oc2ccncc2c1O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 2/20 0.37
ALDH1A1 P00352 2/20 0.37
KDM4C Q9H3R0 2/20 0.37
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 1/20 0.37
KDM6B O15054 1/20 0.37
KDM4A O75164 1/20 0.37
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM4D Q6B0I6 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
GPR35 Q9HC97 1/20 0.37
TSHR P16473 2/20 0.36
APEX1 P27695 1/20 0.36
LMNA P02545 2/20 0.35
MKNK2 Q9HBH9 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3603321 0.86 BRAF (0.39) ALDH1A1KDM4CKDM4EMEN1KDM6B
SCHEMBL4985633 0.81 MCL1 (0.54) MCL1ALDH1A1KDM4ETDP1L3MBTL1
SCHEMBL4986461 0.78 MAP2 (0.45) ALDH1A1KDM4EMAPTKMT2ATSHR
SCHEMBL2564883 0.77 BRAF (0.50) ALDH1A1KDM4EMAPTL3MBTL1TSHR
SCHEMBL14227921 0.74 IDO1 (0.50) ALDH1A1KDM4CKMT2ALMNAMAPK1
SCHEMBL647309 0.74 KMT2A (0.51) MCL1ALDH1A1KDM4EMEN1MAPT
SCHEMBL29502948 0.74 KMT2A (0.51) MCL1ALDH1A1KDM4EMEN1MAPT
SCHEMBL4412867 0.71 HSD11B1 (0.34) MCL1TSHRAPEX1SMN1; SMN2GAA
SCHEMBL4415400 0.71 MAP2K1 (0.49) MAP2K1
SCHEMBL5620680 0.71 MAPT (0.44) ALDH1A1KDM4CKDM4EMEN1KDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080085886-A1 Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide GENENTECH, INC. 2008-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085886-A1 Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide MAP3K2, MAP3K1, MAP2K2 MCL1 61/4885ALDH1A1 1140/4885KDM4C 1481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.